NKILT Therapeutics
Blood & Organ Banks · 1-10 Employees
View Company Info for Free
Overview
Website
www.nkilt.comRevenue
<$5 MillionIndustry
About NKILT Therapeutics
NKILT Therapeutics is a seed-stage biotech company specializing in cell therapy, focusing on an allogeneic, off-the-shelf approach to target cancer using natural receptor binding. The company is developing engineered natural killer (NK) cells to directly attack leukemias and solid tumors, with a unique technology called Chimeric ILT-Receptor (CIR) that enhances immune response. Their innovative platform has the potential to address approximately 50% of cancers by exploiting tumor vulnerabilities. NKILT Therapeutics aims to expand its technology to include other immune cells, enhancing the fight against cancer.Explore more
SIC Code 28,283NAICS Code 32,325Show moreNKILT Therapeutics Org Chart
Compare Similar Companies to NKILT Therapeutics
Compare insights from companies similar to NKILT Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
NKILT Therapeutics Tech Stack
A closer look at the technologies used by NKILT Therapeutics
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NKILT Therapeutics
Sign Up For FreeTo access detailed company insights
NKILT Therapeutics is a seed-stage biotech company specializing in cell therapy, focusing on an allogeneic, off-the-shelf approach to target cancer using natural receptor binding. The company is developing engineered natural killer (NK) cells to directly attack leukemias and solid tumors, with a unique technology called Chimeric ILT-Receptor (CIR)... Read More